Overview

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Status:
Terminated
Trial end date:
2015-12-24
Target enrollment:
Participant gender:
Summary
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Docetaxel